<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:regn="http://regeneron.com/20200818">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_regn_regeneron.com_20200818 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20200817_20200818 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0000872589 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-08-17to2020-08-18" name="dei:EntityCentralIndexKey">0000872589</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-08-17to2020-08-18" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="regn-20200818.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-08-17to2020-08-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-17</xbrli:startDate>
        <xbrli:endDate>2020-08-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0"></p>

<p style="margin: 0pt 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20200817__20200818_zvrWysgQvIhd"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): August 19, 2020 (<span id="xdx_904_edei--DocumentPeriodEndDate_c20200817__20200818_zPIHUOCd0fBk"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">August 18, 2020</ix:nonNumeric></span>)</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityRegistrantName_c20200817__20200818_zm5Xtm1GO92j"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" name="dei:EntityRegistrantName">REGENERON PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified
in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20200817__20200818_zzsRBXCId5gi"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">New York</ix:nonNumeric></span></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other jurisdiction of incorporation)</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 51%"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityFileNumber_c20200817__20200818_zX0yugHLd2z7"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" name="dei:EntityFileNumber">000-19034</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 48%"><span style="font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20200817__20200818_ztpLJtoURmO2"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" name="dei:EntityTaxIdentificationNumber">13-3444607</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>File Number)</b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(I.R.S. Employer</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)&#160;</b></p></td></tr>
<tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20200817__20200818_zH4YzZBQohXi"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" name="dei:EntityAddressAddressLine1">777 Old Saw Mill River Road</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressCityOrTown_c20200817__20200818_zLaNYvLmLwkh"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" name="dei:EntityAddressCityOrTown">Tarrytown</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20200817__20200818_zoFWfnFdfTq7"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: bottom; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressPostalZipCode_c20200817__20200818_zUo30qbnsFp6"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" name="dei:EntityAddressPostalZipCode">10591-6707</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 8pt"><b>(Address of principal executive offices)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 8pt"><b>(Zip Code)</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number,
including area code: (<span id="xdx_90E_edei--CityAreaCode_c20200817__20200818_zGkQPKS5iUl1"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" name="dei:CityAreaCode">914</ix:nonNumeric></span>) <span id="xdx_90C_edei--LocalPhoneNumber_c20200817__20200818_zbavWAthNzWa"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" name="dei:LocalPhoneNumber">847-7000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_904_edei--WrittenCommunications_c20200817__20200818_zhj9KNiNq4Fg"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_900_edei--SolicitingMaterial_c20200817__20200818_zKcvXNXoTagk"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementTenderOffer_c20200817__20200818_zarMHssZVeFi"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20200817__20200818_z4qBQlmrlyH8"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: black 1pt solid; font-size: 10pt; border-image: none; width: 42%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; width: 20%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; width: 38%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20200817__20200818_zUN8Kdy9brS9"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" name="dei:Security12bTitle">Common Stock &#8211; par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20200817__20200818_z58Q7NksZdqa"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" name="dei:TradingSymbol">REGN</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_902_edei--SecurityExchangeName_c20200817__20200818_zDPPdM8D2Tib"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20200817__20200818_zfjrCmQAHz9c"><ix:nonNumeric contextRef="From2020-08-17to2020-08-18" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01.&#160; Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On August 18, 2020, Regeneron Pharmaceuticals,
Inc. (&#8220;<span style="text-decoration: underline">Regeneron</span>&#8221; or the &#8220;<span style="text-decoration: underline">Company</span>&#8221;), F. Hoffman-La Roche Ltd (&#8220;<span style="text-decoration: underline">Roche Basel</span>&#8221;),
and Genentech, Inc. (&#8220;<span style="text-decoration: underline">Genentech</span>&#8221; and, together with Roche Basel, &#8220;<span style="text-decoration: underline">Roche</span>&#8221;) entered into a
global strategic collaboration to develop, manufacture, and commercialize the Company&#8217;s novel investigational two-antibody
&#8220;cocktail&#8221; treatment, consisting of the antibodies REGN10987 and REGN10933 (also known as REGN-COV2) (the &#8220;<span style="text-decoration: underline">Antibody
Product</span>&#8221;), designed to prevent and treat infection from the SARS-CoV-2 virus (the &#8220;<span style="text-decoration: underline">Collaboration</span>&#8221;).
The Collaboration is governed by a collaboration and license agreement (the &#8220;<span style="text-decoration: underline">License Agreement</span>&#8221;), dated August
18, 2020, by and among the Company, Roche Basel, and Genentech. Previously, to expedite the Collaboration, on July 22, 2020 the
Company and Roche Basel entered into a technology transfer agreement to govern the transfer by the Company to Roche Basel of the
process required for the manufacture of the Antibody Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the License Agreement, the
Company has granted to Roche Basel (i) a non-exclusive license to make, import, and export the Antibody Product worldwide, (ii)
a non-exclusive license to develop the Antibody Product worldwide, (iii) a co-exclusive license to obtain regulatory approval for
the Antibody Product throughout the world outside the United States (the &#8220;<span style="text-decoration: underline">Roche Territory</span>&#8221;), and (iv) an exclusive
license to market, commercially distribute, sell, and offer for sale the Antibody Product in the Roche Territory. Under the License
Agreement, Roche Basel has granted to the Company (i) a non-exclusive license to make, import, and export the Antibody Product
worldwide, (ii) a non-exclusive license to develop the Antibody Product worldwide, (iii) an exclusive license to obtain regulatory
approval for the Antibody Product in the United States, and (iv) an exclusive license to market, commercially distribute, sell,
and offer for sale the Antibody Product in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the License Agreement, Roche
and the Company are obligated to dedicate and utilize the equivalent of at least 100,000 liters and at least 40,000 liters, respectively,
of annualized bioreactor capacity on a full-time campaign basis for the manufacture of the Antibody Product, unless otherwise mutually
agreed by the parties or determined by the joint manufacturing committee to be established for the Collaboration. Any worldwide
gross profits from the Antibody Product will be aggregated and shared based on a pre-specified formula, which is estimated to result
in Regeneron receiving approximately 50% - 60% of the worldwide gross profits, depending on the amount of manufactured Antibody
Product delivered by each party. Any profit sharing will commence after the Antibody Product manufactured by Roche receives regulatory
approval and is supplied to the market. Each party will bear its own commercial expenses in its designated territory. In addition,
the parties will be obligated to jointly fund the ongoing Antibody Product Phase 3 COVID-19 prevention study and Phase 1 multi-dose
safety study, as well as any additional new global studies to evaluate further the potential of the Antibody Product in treating
or preventing COVID-19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The term of the License Agreement will
expire seven years after the first commercial sale of an Antibody Product in the European Union unless the parties mutually agree
to extend the term. Either party may terminate the License Agreement in the event of bankruptcy or a material breach of the License
Agreement by the other party that remains uncured for a period of 90 days. In addition, Roche may terminate the License Agreement
upon 30 days&#8217; written notice to the Company if: (i) both of the two specified Antibody Product COVID-19 treatment studies
are placed on clinical hold by the U.S. Food and Drug Administration (the &#8220;<span style="text-decoration: underline">FDA</span>&#8221;) or the European Medicines Agency
that continues for 30 days unless the Company is undertaking reasonable actions to have either such clinical hold removed, in which
case if such clinical hold continues for 90 days; (ii) the Antibody Product has not received an emergency use authorization by
the FDA prior to May 31, 2021; (iii) the Company has not filed for full regulatory approval of the Antibody Product in the United
States prior to May 31, 2021; or (iv) the Company terminates further development of the Antibody Product. Further, if a third party&#8217;s
antibody product for SARS-CoV-2 virus has a safety and efficacy profile that provides a substantial public health benefit compared
to the Antibody Product that is approved, Roche may terminate the License Agreement upon 60 days&#8217; written notice before the
first commercial sale of the Antibody Product and six months&#8217; notice after the first commercial sale of the Antibody Product.
Upon termination of the License Agreement in its entirety, generally all related rights and licenses granted by each party to the
other will terminate on the effective date of the expiration or termination, subject to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The foregoing description of the Collaboration
is qualified in its entirety by reference to the full text of the License Agreement, a copy of which will be filed with the U.S.
Securities and Exchange Commission as an exhibit to the Quarterly Report on Form 10-Q to be filed by the Company for the quarterly
period ending September 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="vertical-align: top; width: 50%">&#160;</td>
    <td style="width: 50%"><span style="font: 10pt Times New Roman, Times, Serif"><b>REGENERON PHARMACEUTICALS,
    INC.&#160;</b></span></td>
    </tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Joseph
J. LaRosa</span></td>
    </tr>
<tr>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Joseph J. LaRosa</span></td>
    </tr>
<tr>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Executive Vice President, General Counsel and Secretary</span></td>
    </tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 19, 2020</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk38Ae2bFhWxihQRX2O7SrDNlk38O5K3NLaIy8KyzHwzQnTEkhamRIbjLEthj1Vdao+Q4RkZbY7BkazWMYSb4cU4z9r65v2BCQUGAzPqylMehMZ6Nw6LGOS4J1VPTUAOYzWA6UZEXz0hezYFWm90CdoWsGOq2aDX/GoT9vpJlqpXU3VAdoZsDKorW/kNfan6sKW7fhBfHaRpIqJOM5FYMt3qb83NeapgXmIVulyL/jf6ADFtSWw= -->
